Back to Journals » Biologics: Targets and Therapy » Volume 6

Review

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors

      
Total article views   HTML views PDF downloads Totals
13,785 Dovepress* 10,059+ 2,455 12,514
PubMed Central* 3,726 1,155 4,881
Totals 13,785 3,610 17,395
*Since 25 September 2012
+Since July 2016

View citations on PubMed Central and Google Scholar